65
Participants
Start Date
November 3, 2021
Primary Completion Date
June 9, 2024
Study Completion Date
June 9, 2024
Ferric Maltol
"Ferric maltol oral suspension: 150 ml amber glass bottle with graduated syringe and adaptor. Oral suspension containing 30 mg elemental iron, in the form of 231.5 mg ferric maltol, in 5 ml suspension~Study dosage: The dose of ferric maltol oral suspension that will be administered for children aged 1 month to \< 2 yrs: 0.1 ml/kg BID, 2 to - 11 yrs: 2.5 ml BID, 12-17 yrs: 5 ml BID."
Ferrous sulfate
"Ferrous sulfate 125 mg/ml (25 mg/ml elemental iron) oral liquid : 15 ml glass bottle.~Study dosage: For ferrous sulfate oral liquid, the dose administered will be for children and adolescents aged 2 years to 17 yrs: 6 mg/kg to the maximum of 4 ml BID."
Penn State Hershey Children's Hospital, Hershey
Levine Cancer Institute, Charlotte
Homestead Research Institute, Homestead
Eminent Clinical Research and Associates, North Lauderdale
Miami Clinical Research, Miami
Medical Research of Westcheste, Miami
Kissimmee Clinical Research Corp, Kissimmee
The Center for Clinical Trials, Saraland
Zion Research, Katy
BRCR Global Texas, Edinburg
Clinical Research Prime, Idaho Falls
Sierra Clinical Research, Las Vegas
MultiCare Health System Institute for Research and Innovation, Tacoma
Hasbro Children's Hospital, Providence
BRCR Global Puerto, San Juan
Noah's Ark Children's Hospital for Wales, Cardiff
Royal Hospital for Sick Children - Edinburgh, Edinburgh
Leicester Royal Infirmary, Leicester
Alder Hey Children's NHS Foundation Trust, Liverpool
Newham University Hospital, London
King's College Hospital, London
Royal Manchester Children's Hospital, Manchester
Nottingham University Hospitals, Nottingham
Lead Sponsor
Shield Therapeutics
INDUSTRY